PMID- 27356739
OWN - NLM
STAT- MEDLINE
DCOM- 20180313
LR  - 20191210
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 7
IP  - 30
DP  - 2016 Jul 26
TI  - Aurora kinase A revives dormant laryngeal squamous cell carcinoma cells via 
      FAK/PI3K/Akt pathway activation.
PG  - 48346-48359
LID - 10.18632/oncotarget.10233 [doi]
AB  - Revival of dormant tumor cells may be an important tumor metastasis mechanism. We 
      hypothesized that aurora kinase A (AURKA), a cell cycle control kinase, promotes 
      the transition of laryngeal squamous cell carcinoma (LSCC) cells from G0 phase to 
      active division. We therefore investigated whether AURKA could revive dormant 
      tumor cells to promote metastasis. Western blotting revealed that AURKA 
      expression was persistently low in dormant laryngeal cancer Hep2 (D-Hep2) cells 
      and high in non-dormant (T-Hep2) cells. Decreasing AURKA expression in T-Hep2 
      cells induced dormancy and reduced FAK/PI3K/Akt pathway activity. Increasing 
      AURKA expression in D-Hep2 cells increased FAK/PI3K/Akt pathway activity and 
      enhanced cellular proliferation, migration, invasion and metastasis. In addition, 
      FAK/PI3K/Akt pathway inhibition caused dormancy-like behavior and reduced 
      cellular mobility, migration and invasion. We conclude that AURKA may revive 
      dormant tumor cells via FAK/PI3K/Akt pathway activation, thereby promoting 
      migration and invasion in laryngeal cancer. AURKA/FAK/PI3K/Akt inhibitors may 
      thus represent potential targets for clinical LSCC treatment.
FAU - Yang, Li-Yun
AU  - Yang LY
AD  - Department of Otolaryngology, Ruijin Hospital, School of Medicine, Shanghai 
      Jiaotong University, Shanghai, China.
FAU - He, Chang-Yu
AU  - He CY
AD  - Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive 
      Surgery, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
FAU - Chen, Xue-Hua
AU  - Chen XH
AD  - Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive 
      Surgery, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
FAU - Su, Li-Ping
AU  - Su LP
AD  - Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive 
      Surgery, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
FAU - Liu, Bing-Ya
AU  - Liu BY
AD  - Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive 
      Surgery, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
FAU - Zhang, Hao
AU  - Zhang H
AD  - Department of Otolaryngology, Ruijin Hospital, School of Medicine, Shanghai 
      Jiaotong University, Shanghai, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Phosphoinositide-3 Kinase Inhibitors)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.2 (Focal Adhesion Kinase 1)
RN  - EC 2.7.10.2 (PTK2 protein, human)
RN  - EC 2.7.11.1 (AURKA protein, human)
RN  - EC 2.7.11.1 (Aurora Kinase A)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
SB  - IM
MH  - Animals
MH  - Aurora Kinase A/*metabolism
MH  - Carcinoma, Squamous Cell/*enzymology/genetics/pathology
MH  - Cell Proliferation/physiology
MH  - Down-Regulation
MH  - Focal Adhesion Kinase 1/antagonists & inhibitors/*metabolism
MH  - Head and Neck Neoplasms/*enzymology/genetics/pathology
MH  - Heterografts
MH  - Humans
MH  - Laryngeal Neoplasms/*enzymology/genetics/pathology
MH  - Male
MH  - Mice
MH  - Mice, Nude
MH  - Phosphatidylinositol 3-Kinases/*metabolism
MH  - Phosphoinositide-3 Kinase Inhibitors
MH  - Protein Kinase Inhibitors/pharmacology
MH  - Proto-Oncogene Proteins c-akt/antagonists & inhibitors/*metabolism
MH  - Signal Transduction/drug effects
MH  - Squamous Cell Carcinoma of Head and Neck
MH  - Transfection
PMC - PMC5217022
OTO - NOTNLM
OT  - Akt
OT  - FAK
OT  - PI3K
OT  - aurora kinase A
OT  - laryngeal cancer
COIS- All authors declare no conflicts interest.
EDAT- 2016/07/01 06:00
MHDA- 2018/03/14 06:00
PMCR- 2016/07/26
CRDT- 2016/07/01 06:00
PHST- 2015/12/29 00:00 [received]
PHST- 2016/06/09 00:00 [accepted]
PHST- 2016/07/01 06:00 [pubmed]
PHST- 2018/03/14 06:00 [medline]
PHST- 2016/07/01 06:00 [entrez]
PHST- 2016/07/26 00:00 [pmc-release]
AID - 10233 [pii]
AID - 10.18632/oncotarget.10233 [doi]
PST - ppublish
SO  - Oncotarget. 2016 Jul 26;7(30):48346-48359. doi: 10.18632/oncotarget.10233.